- VC firm Vivo Capital outlays $740m for biotech investment Pharmaceutical Technology
- Vivo Capital secures $740M to invest in preclinical- and clinical-stage biotechs Fierce Biotech
- Vivo Capital Closes Opportunity Fund FIN News
- Vivo Capital closes on $740m for third cycle of evergreen public fund Venture Capital Journal
- Healthcare specialist Vivo Capital closes third Opportunity Fund cycle at $740m Alternatives Watch
The wire
More investor news
TechCrunch Founder Summit’s agenda revealed: Unlock fundraising, hiring, and AI insights in Boston on November 4 – TechCrunch Venture
a16z is challenging Silicon Valley’s love for drop-outs by launching a school – TechCrunch Venture
Cloud startup Verda raises $189m in funding round led by Emergence Capital – Sifted
Exclusive: Mistral acquires adtech startup Pimento in €12.7m cash-and-shares deal, filings show – Sifted
NATO Innovation Fund co-leads €11M investment in Swedish defence tech outfit Terasi – Tech.eu
Exhibit tables added: One last chance to showcase your startup at TechCrunch Disrupt 2026 – TechCrunch Venture